AQ001V

AQ001V is a preclinical-stage inhaled antiviral formulation being developed by Aquoralon Pharmaceuticals for the treatment of viral respiratory infections. The drug utilizes a proprietary inhalation technology designed to enhance the delivery and efficacy of the active pharmaceutical ingredient within the lungs. While the specific active ingredient and molecular target have not been publicly disclosed, the program is positioned to address viral pathogens that affect the respiratory system, potentially including SARS-CoV-2. The formulation aims to provide high local concentrations of the therapeutic agent while minimizing systemic exposure.